Comparative Pharmacology
Head-to-head clinical analysis: AMIPAQUE versus CONRAY 43.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIPAQUE versus CONRAY 43.
AMIPAQUE vs CONRAY 43
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrizamide, a non-ionic iodinated contrast agent, attenuates X-rays due to iodine content, enhancing radiographic imaging. It distributes in extracellular fluid and does not cross intact blood-brain barrier; in subarachnoid space, it outlines neural structures.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
200-300 mg iodine/kg body weight intravenously, maximum 60 g iodine per administration.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment (up to 20-30 hours in severe renal failure).
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal excretion via glomerular filtration; approximately 90-95% of the dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary route.
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent